✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
DCC-2618 is an investigational drug.
There have been 29 clinical trials for DCC-2618. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2009.
The most common disease conditions in clinical trials are Gastrointestinal Stromal Tumors, Neoplasms, and Premature Birth. The leading clinical trial sponsors are Deciphera Pharmaceuticals LLC, National Heart, Lung, and Blood Institute (NHLBI), and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Recent Clinical Trials for DCC-2618
|Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)||Deciphera Pharmaceuticals LLC||Phase 1/Phase 2|
|A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.||Deciphera Pharmaceuticals LLC||Phase 1|
|A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib||Zai Lab (Shanghai) Co., Ltd.||Phase 2|